Company Overview and News

6
Winter warmers: Why air deals to Bali are heating up

2018-05-23 nzherald.co.nz
Emirates is banking on its new Bali route being popular with surfers by carrying boards for free on a route that is shaping up as a hotly contested one as Air New Zealand faces competition on direct services for the first time.
FGETF ANZLY AIR FGHRY ANZFF ANZFY AIZ

11
Battle of Business Class: The high stakes relaunch for Air New Zealand

2018-05-16 nzherald.co.nz
Just over 5 per cent of passengers fly business class or better but they provide nearly a third of annual global revenue for airlines which totals $1.1 trillion.
FGETF C6L ANZLY AIR FGHRY ANZFF SINGY ANZFY AIZ SINGF

0
Brisbane developer Liz Pidgeon forks out about $1000 to play a round of golf with tennis legend Pat Rafter

2018-05-15 perthnow.com.au
Brisbane developer Liz Pidgeon has forked out about $1000 to play a round of golf with tennis legend Pat Rafter this week.
FGETF FGHRY

6
Air New Zealand fares going up by 5 per cent on domestic routes from Thursday

2018-05-15 nzherald.co.nz
Travel agents say they received the news from the airline yesterday - and today the airline confirmed it could no longer absorb extra costs.
FGETF ANZLY AIR FGHRY ANZFF ANZFY AIZ

6
Airfare wars: Return to Rome for $999 on sale this weekend

2018-05-04 nzherald.co.nz
Cut price airfares to Rome this weekend will drop to $999 and return economy to the Cook Islands will sell for $399.
FGETF ANZLY AIR FGHRY ANZFF ANZFY AIZ

3
Sabre (SABR) Q1 2018 Results - Earnings Call Transcript

2018-05-01 seekingalpha
Good morning and welcome to the Sabre First Quarter 2018 Earnings Conference Call. Please note that today's call is being recorded and is also being broadcast live over the Internet on the Sabre corporate website. This broadcast is the property of Sabre. Any redistribution, retransmission or rebroadcast of this call in any form without the express written consent of the company is strictly prohibited.
FGETF 0753 VA AICAF AFRAF ACDVF AIRC AIRYY FGHRY SABR AFLYY AC

11
The future of flight: Higher fares on the way

2018-04-27 nzherald.co.nz
Airfares for business travellers crept up steadily during the past year and are forecast to climb again this year, shows a report done for the travel industry.
C6L AIR CHEAF SINGY ANZFY CEA AIZ 0670 FGETF ANZLY FGHRY ANZFF SINGF

6
Air New Zealand's Dreamliner disruption: see every cancelled and changed flight

2018-04-19 nzherald.co.nz
Air New Zealand has released details of dozens of cancelled and re-timed international flights due to Dreamliner engine problems.
FGETF ANZLY AIR FGHRY ANZFF ANZFY AIZ

0
Column 8

2018-04-12 smh.com.au
Branching off from the topic of relative density of academics (C8), one of the pet peeves of Tim Ingall from Scottsdale, Arizona, possessor of a fine set of educational post-nominals of his own, is "when someone with academic qualifications is interviewed and we are informed that the person is a Professor at Whatsamatter University (one for the Rocky and Bullwinkle fans), which provides absolutely no information regarding whether the professor is qualified to comment on the matter at hand.
FGETF FGHRY

0
Flight Centre fined $13.2 million for price fixing

2018-04-04 nbr.co.nz
Credit card details are required to authenticate your account. You won't be charged until your trial has ended. Cancel anytime.
FGETF FGHRY

0
Flight Centre fined $12.5 million over international flight price fixing

2018-04-04 abc.net.au
Flight Centre has lost its long-running and expensive legal battle with competition watchdog, the ACCC, after being forced to pay $12.5 million in penalties relating to attempts to fix international flight prices.
FGETF FGHRY

5
Federal Court fines Flight Centre for price-fixing

2018-04-04 perthnow.com.au
FLIGHT Centre’s attempts to fix the value of tickets with three airlines so its “price beat guarantee” didn’t reduce the company’s profits has ended up costing it $12.5 million.
FGETF C6L FGHRY SINGY SINGF

5
Flight Centre cops $12.5 million fine for price fixing

2018-04-04 theage.com.au
Flight Centre's attempts to fix the value of tickets with three airlines so its "price beat guarantee" didn't reduce the company's profits has ended up costing it $12.5 million.
FGETF C6L FGHRY SINGY SINGF

5
Flight Centre cops $12.5 million fine for price fixing

2018-04-04 smh.com.au
Flight Centre's attempts to fix the value of tickets with three airlines so its "price beat guarantee" didn't reduce the company's profits has ended up costing it $12.5 million.
FGETF C6L FGHRY SINGY SINGF

6
New airline battle lines across the Tasman: Filling a superjumbo gap

2018-04-01 nzherald.co.nz
New airline battle lines have been drawn across the Tasman to fill the big gap left by the exit of Emirates' two A380s from Auckland to Australia.
FGETF ANZLY AIR FGHRY ANZFF ANZFY AIZ

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...